Receptos Files For IPO

San Diego-based biopharmaceuticals firm Receptos has filed for an IPO, saying in a filing that it is looking to raise up to $86.3M in an offering on the NASDAQ Global Market. The firm said it intends to list as "RCPT". The firm's IPO is being underwritten by Credit Suisse, Leerink Swann, BMO Capital Markets, and Wedbush PacGrow Life Sciences. The firm is venture backed by ARCH Venture Partners, Flagship Ventures, Lilly Ventures Fund, Polaris Ventures, and Venrock Associates. Receptos is a biopharmaceuticals firm developing treatments for immune disorders; the firm's lead compounds include an oral therapy for treating Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD), and a compound aimed at treating Eosinophilic Esophagitis (EoE).